Research Analysts’ Weekly Ratings Updates for argenex (ARGX)

Several analysts have recently updated their ratings and price targets for argenex (NASDAQ: ARGX):

• 12/18/2025 – argenex was downgraded by analysts at Baird R W from a “strong-buy” rating to a “hold” rating.
• 12/18/2025 – argenex had its “neutral” rating reaffirmed by analysts at Robert W. Baird. They now have a $858.00 price target on the stock, down previously from $924.00.
• 12/17/2025 – argenex had its price target raised by analysts at Royal Bank Of Canada from $860.00 to $925.00. They now have an “outperform” rating on the stock.
• 12/11/2025 – argenex had its price target raised by analysts at Wells Fargo & Company from $1,095.00 to $1,316.00. They now have an “overweight” rating on the stock.
• 12/11/2025 – argenex had its price target raised by analysts at Stifel Nicolaus from $1,028.00 to $1,248.00. They now have a “buy” rating on the stock.
• 12/8/2025 – argenex had its price target raised by analysts at JPMorgan Chase & Co. from $925.00 to $1,100.00. They now have an “overweight” rating on the stock.
• 12/4/2025 – argenex had its price target raised by analysts at Morgan Stanley from $1,070.00 to $1,110.00. They now have an “overweight” rating on the stock.
• 11/24/2025 – argenex had its “peer perform” rating reaffirmed by analysts at Wolfe Research.
• 11/17/2025 – argenex had its price target raised by analysts at Citigroup Inc. from $1,041.00 to $1,124.00. They now have a “buy” rating on the stock.
• 11/14/2025 – argenex had its price target raised by analysts at Wedbush from $880.00 to $1,000.00. They now have an “outperform” rating on the stock.
• 11/7/2025 – argenex had its price target raised by analysts at JPMorgan Chase & Co. from $830.00 to $925.00. They now have an “overweight” rating on the stock.
• 11/4/2025 – argenex had its price target raised by analysts at Piper Sandler from $820.00 to $930.00. They now have an “overweight” rating on the stock.
• 10/31/2025 – argenex had its price target raised by analysts at TD Cowen from $800.00 to $1,146.00. They now have a “buy” rating on the stock.
• 10/31/2025 – argenex had its price target raised by analysts at Royal Bank Of Canada from $850.00 to $860.00. They now have an “outperform” rating on the stock.
• 10/31/2025 – argenex had its price target raised by analysts at Evercore ISI from $775.00 to $910.00. They now have an “outperform” rating on the stock.
• 10/31/2025 – argenex had its price target raised by analysts at HC Wainwright from $774.00 to $915.00. They now have a “buy” rating on the stock.

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.